IntelGenx Technologies Corp (IGXT)

[specular]

Forfivo issues have been on the execution side, not the product side.

From today's numbers they are still capturing less than 3% of the total high dose Bupropion market - and they not only have the best product, they have the only single dose product. So there is no reason they shouldn't be able to increase sales. As bad as Zerbe / Edgemont have been on this (we are on our third year now), I was encouraged by the fact that the royalty for this past quarter was well over $100,000 (and as reported that is double the year before quarter). At less than 3% of the market, if they have finally figured out how to market this thing $1M+ a quarter is very doable (remember the original projection by Zerbe for 2014 was $7M in royalties).

Still think he turns into a mental midget once he takes off the lab coat and progress on the business side is still pathetic - but they are moving in the right direction. I also really liked the patent approvals.